R-ketoprofen

Drug Profile

R-ketoprofen

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Sepracor
  • Class Nonsteroidal anti-inflammatories
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Neuropathic pain; Tinnitus

Most Recent Events

  • 25 Feb 2003 No development reported - Clinical-Phase-Unknown for Tinnitus in USA (unspecified route)
  • 25 Feb 2003 No development reported - Phase-II for Neuropathic pain in USA (PO)
  • 24 Jan 2001 R-ketoprofen is being investigated for use in tinnitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top